Harrow, Inc. Finance Lease, Liability, Undiscounted Excess Amount
Harrow, Inc. (HROW) had Finance Lease, Liability, Undiscounted Excess Amount of $1.00 thousand as of 2022-03-31, per its 10-Q filed 2022-05-05.
Discontinued › Notes › Leases
us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount · last filed 2022-05-05
- 2022-03-31: Finance Lease, Liability, Undiscounted Excess Amount $1.00K.
- 2021-12-31: Finance Lease, Liability, Undiscounted Excess Amount $1.00K.
- 2021-09-30: Finance Lease, Liability, Undiscounted Excess Amount $1.00K.
- 2021-06-30: Finance Lease, Liability, Undiscounted Excess Amount $2.00K.
| Period end | Finance Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2022-03-31 | $1.00K 10-Q · filed 2022-05-05 |
| 2021-12-31 | $1.00K 10-K · filed 2022-03-10 |
| 2021-09-30 | $1.00K 10-Q · filed 2021-11-09 |
| 2021-06-30 | $2.00K 10-Q · filed 2021-08-10 |
| 2021-03-31 | $2.00K 10-Q · filed 2021-05-11 |
| 2020-12-31 | $3.00K 10-K · filed 2021-03-08 |
| 2020-09-30 | $3.00K 10-Q · filed 2020-11-09 |
| 2020-06-30 | $3.00K 10-Q · filed 2020-08-10 |
| 2019-12-31 | $4.00K 10-Q · filed 2020-05-11 |
| 2019-09-30 | $5.00K 10-Q · filed 2019-11-13 |
| 2019-06-30 | $6.00K 10-Q · filed 2019-08-14 |
| 2019-03-31 | $11.00K 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |